在治疗COPD时,每天服用一次或两次支气管扩展剂是否更好?
Maria Gabriella Matera1, Barbara Rinaldi1, Concetta Ambrosio2
1Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Respiratory medicine
|October 25, 2023
概括
对于COPD患者来说,晚上长效肌抗体 (LAMA) 最好控制夜间症状. 长效β-激动剂 (LABAs) 是白天缓解的首选药物,其组合可改善支气管扩张.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 循环节生物学 日间生物
背景情况:
- 夜间和清晨的症状显著影响COPD患者的结果.
- 对于症状性慢性肺炎患者的长效支气管扩展剂的最佳剂量频率 (每天一次或每天两次) 仍在争论中.
- 循环节律影响自主音调和气道口径,影响支气管扩展剂的疗效,这取决于服用时间.
研究的目的:
- 为了评估支气管扩展剂的服用时间对COPD症状控制的影响.
- 为了比较每天服用一次和每天服用两次的长效支气管扩展剂的疗效.
- 确定长效肌抗剂 (LAMA) 和长效β-激动剂 (LABA) 在COPD管理中的最佳时间.
主要方法:
- 对支气管扩展剂的使用时间和COPD症状控制现有证据的审查.
- 对每天服用一次和每天服用两次长期起作用的支气管扩展剂的药理动力学和药理动力学概况的分析.
- 对调查晚上支气管扩展剂给药对呼吸机制和神经驱动的影响的研究进行了审查.
主要成果:
- 晚上服用LAMAs与改善夜间和早晨COPD症状的夜间控制有关.
- LABA似乎更适合用于管理白天呼吸道症状.
- 结合LAMA/LABA疗法,特别是那些具有快速发病的疗法,如阿克利迪尼/佛莫特罗尔,显示出全面控制症状的前景.
结论:
- 调整支气管扩展器的选择和时间以满足个体患者的需要,特别是对于夜间症状至关重要.
- 建议在夜间使用LAMA来治疗COPD的症状.
- 结合LAMAs和LABAs可能会在COPD患者中提供更好的支气管扩张和症状控制.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
01:23Inhaled Medications
288
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
288
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
278
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
278
01:17Drugs Used in Lower Respiratory Disorders: Overview
458
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
458
01:22Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K